News | August 22, 2013

Michigan Tech Professor Probes Hypertension, Congestive Heart Failure

Qinghui Chen looks to decipher an elusive component with both diseases

August 22, 2013 — Qinghui Chen, assistant professor in Michigan Tech’s kinesiology and integrative physiology department, wants to get to the bottom of two cardiovascular diseases: hypertension and congestive heart failure.

Hypertension is high blood pressure, which contributes to stroke, heart failure and kidney failure. Congestive heart failure is the weakening and inability of the heart to supply sufficient blood flow to meet the needs of the body.

Both are chronic and dangerous — and common worldwide: up to 10 percent of people over age 65 experience congestive heart failure; up to 25 percent are affected by hypertension.

There is an elusive component with both diseases: they agitate the central nervous system, but it is unknown how. Chen says his goal is to decipher these neural mechanisms.

“We know there’s a neural part of these two diseases,” he said, “but we don’t completely understand what’s going on. There’s a gap in the science.”

Exercise also induces significant changes of neural activity, and Chen addresses the role of exercise in mediating the two diseases. “This is important work,” he said. “If we can identify the mechanism, then we can develop a treatment.”

Chen has gone from the clinician to the scientist. He went to medical school in China, then earned a Ph.D. in cardiovascular physiology in Japan, focusing on figuring out the central nervous mechanism of cardiovascular disease.

He came to Tech in 2010 from the University of Texas in San Antonio. In 2009, he received the Recognition Award for Meritorious Research by the Central Nervous Section of the American Physiological Society.

For more information: www.mtu.edu

Related Content

American Heart Association Announces New Hypertension Center Certification
News | Hypertension | July 05, 2018
Physician practices now have access to new resources to improve their standard of quality care for hypertension...
YMCA and American Heart Association Partner to Improve Blood Pressure Control
News | Hypertension | April 05, 2018
YMCA of the USA (Y-USA) and the American Heart Association (AHA) are combining efforts to help more people better...
Higi Implementing New ACC/AHA Blood Pressure Guidelines at 11,000 North American Stations
News | Hypertension | March 28, 2018
Population health enablement company Higi announced their commitment to implement the 2017 American College of...
Petaluma Health Center Wins 2017 HIMSS Davies Award for Hypertension Control Program
News | Hypertension | February 16, 2018
February 16, 2018 — California’s Petaluma Health Center (PHC) was recently awarded a 2017 Healthcare Information and
SPRINT Trial Data Support New AHA/ACC Hypertension Guidelines
News | Hypertension | November 16, 2017
Findings from a landmark study funded by the National Institutes of Health (NIH) support a key component of the new...
Marijuana Associated With Three-Fold Risk of Death From Hypertension
News | Hypertension | September 14, 2017
Marijuana use is associated with a three-fold risk of death from hypertension, according to research published recently...
Text Messaging Could Help Tackle High Blood Pressure in At-Risk Patients

Image courtesy of Michigan Medicine

News | Hypertension | September 06, 2017
A new National Institutes of Health-funded hypertension trial will examine the possibility of using an emergency...
MobiusHD Device Shows Promise in Treatment of Resistant Hypertension
News | Hypertension | August 30, 2017
Vascular Dynamics Inc. announced interim results of the company’s first-in-human trial of its MobiusHD implant...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension | August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Bayer Now Enrolling Patients for Global Pulmonary Arterial Hypertension Study
News | Hypertension | July 05, 2017
Bayer has enrolled the first patient in a global Phase IV study assessing the clinical effects of riociguat in patients...
Overlay Init